| Literature DB >> 23662126 |
Wen Dai1, Xi Liu, Zhichen Zhang, Jianxin Chen, Rongjuan Guo, Hong Zheng, Xianglan Jin, Shaoxin Wen, Yibo Gao, Tiangang Li, Peng Lu, Yunling Zhang.
Abstract
Prompt and accurate diagnosis of acute ischemic stroke is critical to seek acute therapy. In traditional Chinese medicine (TCM) science, there is a comprehensive system of diagnosis and medical care of acute ischemic stroke. Here we introduce a two-level model for the analysis of TCM syndrome of acute ischemic stroke. Owing to the limitation of sample size and imbalance, we focused on the analysis of wind-phlegm collateral obstruction syndrome (Feng Tan Yu Zu Zheng). Firstly, a Support-Vector-Machine- (SVM-) based diagnostic model was set up through selection of core symptoms. After pairwise undersampling, we improved the performance of prediction and generated the core symptoms-based diagnostic model of wind-phlegm collateral obstruction syndrome. Next, Pathway Pattern-based method and MetaDrug platform were used to shed light on the molecular basis of the significance of core symptoms in three complementary aspects: symptom-gene-pathway multilayer correlation network, enriched pathways, and most relevant interaction network. The integration of diagnostic model and molecular mechanism analysis creates an interesting perspective for better understanding the syndrome. The two-level model would provide a new opportunity for the study of TCM syndromes.Entities:
Year: 2013 PMID: 23662126 PMCID: PMC3638621 DOI: 10.1155/2013/293010
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The framework of the two-level model for analysis of syndrome of acute ischemic stroke. Firstly, a diagnostic model of syndrome is generated based on selected core symptoms in the macro level. Then molecular mechanism analysis of core symptoms in the micro level is undertaken to shed light on the molecular basis of the significance of core symptoms.
Samples of wind-phlegm collateral obstruction syndrome.
| Dataset | Positive | Negative | Total | Ratio | Features |
|---|---|---|---|---|---|
| Wind-phlegm collateral obstruction syndrome | 120 | 46 | 166 | 2.61 : 1 | 102 |
Information gains for the remaining 62 symptoms.
| Symptom | Information gain |
|---|---|
| Greasy fur | 0.041751 |
| Thready pulse | 0.032381 |
| Sublingual vein bruising | 0.030248 |
| Deep pulse | 0.029555 |
| Slippery pulse | 0.023376 |
| Taut pulse | 0.022498 |
| Drowsiness | 0.020716 |
| Red tongue | 0.02046 |
| Dark purple lips | 0.015375 |
| Excessive salivation | 0.014193 |
| Dim complexion | 0.013139 |
| Heat in the palms and soles | 0.013014 |
| Headache | 0.013014 |
| Dizziness | 0.010641 |
| Fatigue | 0.009921 |
| Dry stool and oliguria | 0.009029 |
| Emotional lability | 0.008032 |
| Timid low voice | 0.006736 |
| Constipation | 0.005297 |
| Numbness | 0.004979 |
| Thick fur | 0.004949 |
| High-pitched, coarse voice | 0.004901 |
| Limb limp | 0.004516 |
| Vomiting | 0.004181 |
| Night sweat | 0.003487 |
| Red face and eyes | 0.003487 |
| Limbs twitching | 0.00335 |
| Hand, foot swelling | 0.00335 |
| Pale tongue | 0.00335 |
| Plump tongue | 0.00333 |
| Purplish tongue | 0.003244 |
| Shortness of breath | 0.003108 |
| Thin fur | 0.002897 |
| Dull expression | 0.002566 |
| Yellow fur | 0.002244 |
| Spasm of nape | 0.001819 |
| Aching and weakness | 0.001818 |
| Sweat when quite | 0.001461 |
| Wry tongue | 0.001401 |
| Poor appetite | 0.00134 |
| Dark tongue | 0.001255 |
| Fatigue and drowsiness | 0.001208 |
| Pale red tongue | 0.001147 |
| Restless | 0.000649 |
| Sticky phlegm | 0.000649 |
| Uneven pulse | 0.000649 |
| Overweight | 0.000615 |
| Vexation and irritability | 0.000577 |
| Fever | 0.000412 |
| Palpitate | 0.000369 |
| Pale complexion | 0.000137 |
| Dry stool and constipation | 4.85 |
| Apathy | 3.93 |
| White fur | 1.83 |
| Bitter taste in the mouth | 1.72 |
| Reddish yellow urine | 1.17 |
| Tinnitus | 1.06 |
| Pale tongue | 1.06 |
| Sweat after little movement | 5.33 |
| Dark purple lips and dim complexion | 5.33 |
| Ecchymosis on tongue | 4.92 |
| Predilection for cold drink | 1.96 |
Figure 2The accuracies of classification schemes based on different groups of symptoms. Symptoms whose information gains are above the threshold are selected. The black line indicates accuracies of models based on different groups of symptoms, which helps to select core symptoms. The red line presents the accuracy of the original classification scheme without feature selection as a comparison.
Figure 3Distribution of sensitivity and specificity. Blue boxes indicate the distribution for the original classification scheme without feature selection. Green boxes indicate the distribution for the classification scheme based on core symptoms.
Figure 4The accuracies of classification schemes after pairwise undersampling. Two samples whose Euclidean distance is below the threshold are combined. The black line indicates accuracies of models after pairwise undersampling based on different distance thresholds. The red line presents the accuracy of the original classification scheme based on core symptoms without undersampling as a comparison.
Figure 5Distribution and tendency of sensitivity and specificity. (a) Boxes of different colours indicate distribution for classification schemes with different thresholds of Euclidean distances. (b) Black and red lines indicate the tendency of sensitivity and specificity, respectively, which is calculated by averaging the 100 experiments.
Figure 6G-means for classification schemes with different distance thresholds. Black bars indicate G-mean for the original classification scheme without feature selection. Red bars indicate the rise in G-mean for classification scheme based on core symptoms. Blue bars indicate the rise in G-mean for classification schemes after pairwise undersampling.
Corresponding HPO terms for core symptoms.
| Core symptom | HPO terms |
|---|---|
| Greasy fur | Smooth tongue (HP:0010298) |
| Thready pulse | None |
| Sublingual vein bruising | Abnormality of oral frenula (HP:0000190), tongue nodules (HP:0000199), glossitis (HP:0000206), and tongue telangiectasia (HP:0000227) |
| Deep pulse | None |
| Slippery pulse | None |
| Taut pulse | None |
| Drowsiness | Somnolence (HP:0001262), drowsiness (HP:0002329), and paroxysmal drowsiness (HP:0002330) |
| Red tongue | Tongue telangiectasia (HP:0000227) |
| Dark purple lips | Thick lower lip vermilion (HP:0000179), pursed lips (HP:0000205), lip telangiectasia (HP:0000214), thick upper lip vermilion (HP:0000215), and lip freckle (HP:0010798) |
| Excessive salivation | Abnormality of parotid gland (HP:0000197), drooling (HP:0002307), excessive salivation (HP:0003781), abnormality of the salivary glands (HP:0010286), and abnormality of salivation (HP:0100755) |
| Dim complexion | Pallor (HP:0000980), dull facial expression (HP:0008769) |
| Heat in the palms and soles | Palmoplantar hyperhidrosis (HP:0007410) |
| Headache | Migraine (HP:0002076) and headache (HP:0002315) |
| Dizziness | Vertigo (HP:0002321) |
| Fatigue | Syncope (HP:0001279), muscle weakness (HP:0001324), generalized muscle weakness (HP:0003324), and fatigable weakness (HP:0003473) |
| Dry stool and oliguria | Constipation (HP:0002019) and oliguria (HP:0100520) |
| Emotional lability | Emotional lability (HP:0000712) and mood swings (HP:0000720) |
| Timid low voice | Abnormally low-pitched voice (HP:0010300) and weak cry (HP:0001612) |
| Constipation | Constipation (HP:0002019) |
| Numbness | Impaired vibratory sensation (HP:0002495) and reduced consciousness/confusion (HP:0004372) |
| Thick fur | None |
| High-pitched, coarse voice | High-pitched, coarse voice (HP:0008377) |
| Limb limp | Distal muscle weakness (HP:0002460), limb muscle weakness (HP:0003690), and proximal muscle weakness (HP:0003701) and lower limb muscle weakness (HP:0007340) |
| Vomiting | Vomiting (HP:0002013) and nausea and vomiting (HP:0002017) |
Pathway pattern underlying core symptoms.
| Symbol | Pathway entry | Pathway description | count |
|---|---|---|---|
| 1a | hsa01100 | Metabolic pathways | 57 |
| 1b | hsa04151 | PI3K-Akt signaling pathway | 16 |
| 1c | hsa05200 | Pathways in cancer | 16 |
| 1d | hsa05010 | Alzheimer's disease | 13 |
| 1e | hsa04010 | MAPK signaling pathway | 13 |
| 1f | hsa05016 | Huntington's disease | 12 |
| 1g | hsa04510 | Focal adhesion | 12 |
| 1h | hsa00280 | Valine, leucine, and isoleucine degradation | 11 |
| 1i | hsa05012 | Parkinson's disease | 11 |
| 1j | hsa00190 | Oxidative phosphorylation | 11 |
| 1k | hsa04974 | Protein digestion and absorption | 10 |
| 1l | hsa03010 | Ribosome | 9 |
| 1m | hsa04810 | Regulation of actin cytoskeleton | 9 |
|
| |||
| 2a | hsa05012; hsa05016 | Parkinson's disease and Huntington's disease | 11 |
| 2b | hsa05010; hsa05012 | Alzheimer's disease and Parkinson's disease | 11 |
| 2c | hsa00190; hsa05010 | Oxidative phosphorylation and Alzheimer's disease | 11 |
| 2d | hsa00190; hsa05012 | Oxidative phosphorylation and Parkinson's disease | 11 |
| 2e | hsa05010; hsa05016 | Alzheimer's disease and Huntington's disease | 11 |
| 2f | hsa00190; hsa05016 | Oxidative phosphorylation and Huntington's disease | 11 |
|
| |||
| 3a | hsa00190; hsa05012; hsa05016 | Oxidative phosphorylation, Parkinson's disease, and Huntington's disease | 11 |
| 3b | hsa00190; hsa05010; hsa05016 | Oxidative phosphorylation, Alzheimer's disease, and Huntington's disease | 11 |
| 3c | hsa00190; hsa05010; hsa05012 | Oxidative phosphorylation, Alzheimer's disease, and Parkinson's disease | 11 |
| 3d | hsa05010; hsa05012; hsa05016 | Alzheimer's disease, Parkinson's disease, and Huntington's disease | 11 |
|
| |||
| 4a | hsa00190; hsa05010; hsa05012; hsa05016 | Oxidative phosphorylation, Alzheimer's disease, Parkinson's disease, and Huntington's disease | 11 |
Figure 7Symptom-gene-pathway multilayer correlation network. Symptom nodes are labelled with names of core symptoms. Gene nodes are labelled with gene names. Pathway nodes are labelled with symbols of the association rules of pathway pattern, which has been specified in Table 4.
Figure 8Enrichment Analysis by Pathway Maps. A P value is assigned to each pathway and the pathways are ranked by −log(P value).
Figure 9The pathway map of oxidative phosphorylation. Hexagons indicate input genes (e.g., NDUFA1, NDUFB3).
Figure 10The pathway map of leucine, isoleucine, and valine metabolism. Hexagons indicate input genes (e.g., MCC, IVD).
Figure 11The pathway map of urea cycle. Hexagons indicate input genes (e.g., NAGS, CPSM).
Figure 12Most relevant interaction network. Thick cyan lines indicate the fragments of canonical pathways. Upregulated input genes are marked with red circles (e.g., B-Raf, PMP22).